Journal of Endotoxin Research

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reisser, D.
Right arrow Articles by Jeannin, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Reisser, D.
Right arrow Articles by Jeannin, J.-F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Endotoxin Research, Vol. 5, No. 4, 189-195 (1999)
DOI: 10.1177/09680519990050040501

Lipid A OM-174 increases the natural killer activity of peripheral blood cells from breast cancer patients

Danièle Reisser

Cancer Immunology and Immunotherapy Laboratory, EPHE-INSERM U517, Medicine and Pharmacy Faculty, Dijon, France, reisserd{at}satie.u-bourgogne.fr

Laurent Arnould

Anatomo-Pathology Service, Centre Georges F Leclerc, Dijon, France

Marc Maynadié

Biological Haematology Service, CHU, Dijon, France

Catherine Belichard

Chirurgy Department, Centre Georges F Leclerc, Dijon, France

Bruno Coudert

Oncology Department, Centre Georges F Leclerc, Dijon, France

Jean-François Jeannin

Cancer Immunology and Immunotherapy Laboratory, EPHE-INSERM U517, Medicine and Pharmacy Faculty, Dijon, France

Natural killer (NK) cells have been implicated in immune surveillance against tumors, but their activity is often impaired in cancer patients. Lipopolysaccharides (LPSs) are known to enhance NK activity, but their toxicity prevents their use in humans. OM-174, a purified 3,3'-O-deacylated Escherichia coli lipid A, is able to cure established tumors in the rat with little toxicity. We tested the ability of OM-174 to stimulate in vitro the lytic potential of peripheral blood cells from patients with non-metastatic breast tumor (n = 48). After 24 h pre-incubation of nylon—non-adherent cells with OM-174, increased antitumor activity was observed toward the NK-sensitive target cells K562 but not the lymphokine-activated killer (LAK)-sensitive target cells Daudi. Both NK cells and a non-NK population are involved in this cytotoxicity. So, although the basal NK activity of blood cells was lower in tumor-bearing patients than in healthy donors, OM-174 may increase their toxicity toward cancer cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?